On July 30, Johnson & Johnson declined 3.23% in regular trading, trading at $255.19/share, with turnover of $425 million. The decline was triggered by the company's announcement of a strategic agreement with Sail Biomedicines, obtaining an exclusive option to acquire the biotech firm for $2.58 billion to advance its in vivo CAR-T therapy platform for immune-mediated diseases.

Under the agreement terms, Johnson & Johnson will make total initial payments of $785 million, including a $465 million equity investment, plus additional contingent payments of up to $140 million tied to development milestones. On the same day, the company also confirmed completion of its acquisition of Firefly Bio to accelerate next-generation oncology innovation. The concentration of large-scale M&A expenditures and explicit earnings dilution expectations weighed on investor sentiment in the near term.

Separately, Johnson & Johnson's Rybrevant Faspro received FDA Priority Review designation as a potential first-in-class EGFR/MET-targeting subcutaneous therapy for advanced head and neck cancer. The company maintained its full-year sales guidance of $100.8-101.4 billion and adjusted EPS outlook of $10.96-$11.11.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)